Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2020

Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, Myvac, Publication, publication key en, TG4050

Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models

20200622b – BT-001_AACR poster EN

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020

20200622a – Transgene PR AACR 3 posters

Published 22 June 2020
Categorized as 2020, BT-001, Invir.IO, Myvac, Press release

Combined General Meeting of May 27, 2020

20200527 TG AGM 2020

Published 27 May 2020
Categorized as 2020, Press release

Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors

20200515 BT-001_AACR curtain raiser EN

Published 15 May 2020
Categorized as 2020, BT-001, Invir.IO, Press release

Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050

20200515_AACR myvac curtain raiser EN

Published 15 May 2020
Categorized as 2020, Myvac, Press release, TG4050

Transgene reports Q1 2020 financial position and business update

20200506 TG FINANCIAL T1- US

Published 6 May 2020
Categorized as 2020, Press release

Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses

20200504 – TG Vaxxell EN

Published 4 May 2020
Categorized as 2020, Press release

Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19

20200402PR-EN availability URD 2019

Published 3 April 2020
Categorized as 2020, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020

20200403 – availability doc AG – EN

Published 3 April 2020
Categorized as 2020, Press release

Posts pagination

Newer posts Page 1 … Page 4 Page 5 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu